<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52058">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02038530</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2013-4D</org_study_id>
    <nct_id>NCT02038530</nct_id>
  </id_info>
  <brief_title>The Designer D-dimer Deep Vein Thrombosis Diagnosis (4D) Study</brief_title>
  <acronym>4D</acronym>
  <official_title>D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cohort study that will assess a new diagnostic management strategy for suspected
      Deep Vein Thrombosis in outpatients.The new diagnostic strategy is designed to reduce the
      use of ultrasound testing on the day of presentation, and reduce repeat ultrasound testing a
      week after an initial normal test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicentre, cohort study that will assess a new diagnostic
      management strategy for suspected Deep Vein Thrombosis in outpatients. The new diagnostic
      strategy is designed to reduce the use of ultrasound testing on the day of presentation, and
      reduce repeat ultrasound testing a week after an initial normal test. Less ultrasound
      testing will be performed because: i) more patients will have deep vein thrombosis excluded
      by combinations of Clinical Pretest Probability and D-dimer results on the day of
      presentation; and, ii) in those who still need an ultrasound, a repeat ultrasound a week
      after a normal result will only be performed if the D-dimer result is markedly abnormal at
      initial presentation. The safety of this management strategy will be established by
      demonstrating a very low rate of proximal Deep Vein Thrombosis or Pulmonary Embolism during
      90 days follow-up in patients who had anticoagulant therapy withheld in response to negative
      diagnostic testing. Diagnostic test utilization will be assessed. All clinical outcomes will
      be adjudicated by a central independent adjudication committee that will be blind to initial
      D-dimer measurements and patient management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Confirmed symptomatic proximal Deep Vein Thrombosis</measure>
    <time_frame>within 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome is confirmed symptomatic proximal Deep Vein Thrombosis (including involvement of the calf vein trifurcation but not isolated more distal Deep Vein Thrombosis; or pulmonary embolism (not including isolated sub-segmental abnormalities on Computed Tomography Pulmonary Angiogram; within 90 days (± 7 days for follow-up assessment) that is not diagnosed by scheduled diagnostic testing (includes events that occur between initial and scheduled follow-up proximal ultrasound examinations).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Pretest Probability/ D-dimer/ Compression Ultrasound subgroups</measure>
    <time_frame>within 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome in the following subgroups:
Low Clinical Pretest Probability and D-dimer &lt;1000 ug/L
Moderate Clinical Pretest Probability and D-dimer &lt;1000 ug/L
High Clinical Pretest Probability and D-dimer &lt;500 ug/L
Low Clinical Pretest Probability and D-dimer 1000-2999 ug/L and  negative initial ultrasound
Moderate Clinical Pretest Probability and D-dimer 1000-2999 ug/L and negative initial ultrasound
High Clinical Pretest Probability and D-dimer 500-1499 ug/L and negative initial ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>within 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death within 90 days (± 7 days for follow-up assessment).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Suspected Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>No Ultrasound</arm_group_label>
    <description>Low or Moderate Clinical Pretest Probability and D-dimer &lt; 1000 ug/L; High Clinical Pretest Probability and D-dimer &lt; 500 ug/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound Required</arm_group_label>
    <description>Low or Moderate Clinical Pretest Probability and D-dimer 1000 - 3000 ug/L; High Clinical Pretest Probability and D-dimer 500 - 1500 ug/L</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and females outpatients with a suspected Deep Vein Thrombosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1)  Consecutive outpatients (i.e. non-hospitalized patients) with clinically suspected
        Deep Vein Thrombosis.

        Exclusion Criteria:

          1. Age less than 18 years.

          2. Treated with full-dose anticoagulation for ≥ 24 hours.

          3. Ultrasound of the leg already performed.

          4. Requires an ultrasound of the leg for an indication other than    suspected Deep Vein
             Thrombosis    (e.g. suspected bleeding).

          5. Ongoing need for anticoagulant therapy.

          6. Suspected Pulmonary Embolism.

          7. Superficial venous thrombosis that requires, or may require, anticoagulant therapy.

          8. Life expectancy less than 3 months.

          9. Previously confirmed episode of Deep Vein Thrombosis.

         10. Geographic inaccessibility which precludes follow-up.

         11. Known pregnancy.

         12. Unable to give informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clive Kearon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OCOG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana Spadafora</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42655</phone_ext>
    <email>spadafl@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa N Rudd-Scott, RN BScN MN</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>43793</phone_ext>
    <email>ruddl@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Juravinski Cancer Hospital</name>
      <address>
        <city>Ham</city>
        <state>Ontario</state>
        <zip>L8V1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Stevens, RN</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>43784</phone_ext>
      <email>stevensp@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Clive Kearon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon M Bates, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter L Gross, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfanzo Iorio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lori-Ann Linkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Takach-Lapner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Weitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - McMaster</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon M Bates, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>73928</phone_ext>
      <email>batesm@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Sardo, RN</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>76984</phone_ext>
      <email>sardola@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Shannon M Bates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Hamilton General</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Zondag, RN</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44807</phone_ext>
      <email>zondagm@hhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alla Glushchenko</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>43784</phone_ext>
      <email>glushcha@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sam Schulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Eikelboom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ocog.ca</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 20, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Vein Thrombosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
